-
Anti-ROR1 Antibody: Applied Research Workflows
2026-08-11
Build reproducible ROR1 binding, cell-surface phenotyping, and pathway-blocking experiments with Zilovertamab. This workflow also shows how to use the antibody as an exploratory perturbation in DON-induced liver injury studies without overstating evidence beyond the reference model.
-
V5 Epitope Tag Peptide: Assay Design Guide
2026-08-11
Learn how the V5 Epitope Tag Peptide and GKPIPNPLLGLDST peptide support rigorous protein-detection workflows. This guide connects molecular assay design with antibody-binding kinetics, helping researchers distinguish tag specificity, epitope accessibility, and imaging performance.
-
Annexin V Workflows for Apoptosis Research
2026-08-10
Annexin V, human recombinant, converts phosphatidylserine externalization into a practical readout for early cell death, from flow cytometry to tissue-based studies. This guide combines assay setup, quantitative workflow choices, in vivo context, and troubleshooting for reproducible cell death research.
-
Cyclic Pifithrin-α: p53 Inhibition
2026-08-09
A translational framework for using Cyclic Pifithrin-α hydrobromide as a p53 inhibitor in apoptosis, DNA-damage, and hypothesis-generating neuroinflammation workflows, informed by the CGRP/SP–Piezo2 findings in trigeminal neuralgia.
-
Recombinant Human FGF-19: Renal Assay Workflows
2026-08-08
Use Recombinant Human FGF-19 to connect endocrine signaling, receptor biology, and metabolic regulation research with controlled renal cell assays. This guide combines product-specific handling, FGF-19 and FGFR4 binding considerations, and a practical framework for testing links to p38 MAPK-associated pyroptosis without overstating the current evidence.
-
Z-VAD-FMK in Ferroptosis and Apoptosis Workflows
2026-08-07
Z-VAD-FMK helps separate caspase-dependent apoptosis from ferroptotic death in drug-response experiments. This practical workflow connects caspase activity measurement with the OTUD3–SLC7A11 mechanism underlying sunitinib resistance in clear cell renal cell carcinoma.
-
Solanesol (B8776): Technical Use, Protocols, and Limitations
2026-08-07
Solanesol is a high-purity polyisoprenoid alcohol designed for membrane-associated research applications, including apoptosis research, DNA damage and repair studies, and metabolic enzyme assays. It is unsuitable for aqueous or ethanol-based workflows and requires specific handling protocols to maintain experimental integrity.
-
DMG-PEG2000-NH2: Transforming Liposomal Drug Delivery Workfl
2026-08-06
DMG-PEG2000-NH2 stands out as an NH2-PEG derivative that streamlines lipid nanoparticle and liposomal drug delivery protocols. Its amine-reactive chemistry and exceptional solubility enable precise bioconjugation and robust encapsulation of therapeutics, making it indispensable for modern biomedical research.
-
ATRX Deficiency Increases Sensitivity to PDGFR Inhibitors in
2026-08-06
Pladevall-Morera et al. demonstrate that ATRX-deficient high-grade glioma cells are significantly more sensitive to receptor tyrosine kinase and selective PDGFRα/β inhibitors, suggesting ATRX status as a determinant for targeted therapy response. This work provides a foundation for integrating ATRX mutation analysis into the clinical evaluation of PDGFR inhibition strategies in aggressive glioma.
-
Salinomycin: Polyether Ionophore Antibiotic for HCC Research
2026-08-05
Salinomycin is a polyether ionophore antibiotic with high potency against hepatocellular carcinoma (HCC) cells. It operates via Wnt/β-catenin pathway inhibition and ABC drug transporter blockade, resulting in apoptosis and reduced proliferation. Rigorous in vitro and in vivo data support its use in cancer cell research models.
-
Neurotensin: Precision Neurotensin Receptor 1 Activator for
2026-08-05
Neurotensin (CAS 39379-15-2) is the gold standard for dissecting GPCR trafficking and miRNA regulation, with unique advantages for gastrointestinal cell models. This guide decodes optimized workflows, troubleshooting tips, and the impact of advanced spectral interference removal for higher assay fidelity.
-
MMP-2 Responsive Liposomes Remodel Tumor Immunosuppression
2026-08-04
The referenced study introduces a dual-targeting, MMP-2 responsive liposomal system for sequential delivery of a PD-1/PD-L1 blockade peptide and an IDO inhibitor in breast cancer. This innovation remodels the immunosuppressive tumor microenvironment, restoring T cell function and enhancing combination immunotherapy efficacy.
-
BIIE 0246: Bridging NPY Y2R Antagonism from Bench to Bedside
2026-08-04
Explore how BIIE 0246, a potent neuropeptide Y Y2 receptor antagonist, is redefining translational neurocardiac and metabolic research. This article integrates mechanistic insight, cutting-edge experimental validation, and strategic guidance for leveraging Y2R antagonism in emerging disease models, with a focus on the adipose-neural axis and arrhythmia pathogenesis.
-
Wortmannin in Antiviral Research: PI3K Inhibition Beyond Can
2026-08-03
Explore how Wortmannin, a potent PI3K inhibitor, uniquely advances antiviral strategies and mechanistic cell biology. This article delivers fresh perspective by analyzing Wortmannin's role in clathrin-mediated endocytosis and viral entry, revealing opportunities for innovative assay design.
-
SEMA3E Drives Beige Adipocyte Differentiation via β-Catenin
2026-08-03
This study identifies Semaphorin 3E (SEMA3E) as a key regulator of beige adipocyte differentiation and thermogenesis in mice, acting through β-catenin signaling. The findings highlight new mechanistic links between SEMA3E, mitochondrial function, and energy metabolism, with implications for metabolic disorder research.